GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (MIL:1CVAC) » Definitions » Total Liabilities

CureVac NV (MIL:1CVAC) Total Liabilities : €106.2 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is CureVac NV Total Liabilities?

CureVac NV's Total Liabilities for the quarter that ended in Dec. 2024 was €106.2 Mil.

CureVac NV's quarterly Total Liabilities declined from Jun. 2024 (€180.30 Mil) to Sep. 2024 (€129.49 Mil) and declined from Sep. 2024 (€129.49 Mil) to Dec. 2024 (€106.22 Mil).

CureVac NV's annual Total Liabilities declined from Dec. 2022 (€327.22 Mil) to Dec. 2023 (€271.31 Mil) and declined from Dec. 2023 (€271.31 Mil) to Dec. 2024 (€106.22 Mil).


CureVac NV Total Liabilities Historical Data

The historical data trend for CureVac NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Total Liabilities Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial 800.01 469.77 327.22 271.31 106.22

CureVac NV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 271.31 243.52 180.30 129.49 106.22

CureVac NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CureVac NV's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=72.348+(33.644+-3.2474023470286E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.227+0+0)
=106.2

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=802.827-696.608
=106.2

CureVac NV's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=72.348+(33.644+-3.2474023470286E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.227+0+0)
=106.2

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=802.827-696.608
=106.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of CureVac NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV Business Description

Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV Headlines

No Headlines